Short answer: Brazzein is a naturally occurring, heat-stable sweet-tasting protein isolated from the fruit of the West African plant Pentadiplandra brazzeana. It is approximately 500–2,000 times sweeter than sucrose by weight, provides zero calories, does not raise blood glucose or insulin, and does not require the metabolic processing that artificial sweeteners such as aspartame, sucralose and saccharin do. A randomised controlled trial found that brazzein-sweetened ice cream produced a significantly lower glycaemic response than sucrose-sweetened ice cream in patients with metabolic dysfunction-associated steatotic liver disease. For patients who need to avoid artificial sweeteners — due to phenylketonuria, migraine triggers, gut microbiome concerns or personal preference — brazzein represents a protein-based alternative. In Malaysia, a compounding pharmacy can incorporate brazzein into customised supplement formulations on a prescriber’s specification under Good Compounding Practice (GCP).
What Brazzein Is — and Why It Is Different from Artificial Sweeteners
Brazzein is a small, heat-stable protein (molecular weight approximately 6.5 kDa) composed of 54 amino acids. It is one of several known sweet-tasting proteins — others include thaumatin (from the katemfe fruit), monellin (from serendipity berry) and miraculin (from miracle fruit). What distinguishes brazzein is its exceptional sweetness intensity (500–2,000 times sweeter than sucrose), its heat stability (it retains sweetness after heating to 98°C for 2 hours), and its clean, sugar-like taste profile with no bitter or metallic aftertaste.
Unlike artificial sweeteners — aspartame, sucralose, saccharin, acesulfame-K and neotame — brazzein is a protein. This means it is digested into amino acids in the gastrointestinal tract, just like any other dietary protein. It does not require the liver to metabolise a synthetic molecule, does not activate the same gut-brain signalling pathways that some artificial sweeteners do, and does not carry the same concerns about gut microbiome disruption that have been raised for certain non-nutritive sweeteners.
A systematic review of the allergenicity assessment of plant-derived sweet proteins — including brazzein — examined in silico, in vitro, in vivo and clinical approaches to evaluating the safety of these novel sweeteners. The review concluded that plant-derived sweet proteins generally show low allergenic potential, though individual assessment is required for each protein (Hidayati et al., Molecules, 2026; PMID 42123790).
Clinical Evidence for Brazzein
Glycaemic Response Trial
The most directly relevant clinical study of brazzein to date is a randomised controlled double-blind crossover trial that evaluated the effect of sucrose-free brazzein-sweetened ice cream on continuously monitored glycaemic response in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial found that the brazzein-sweetened product produced a significantly lower glycaemic response compared with the sucrose-sweetened control, without triggering compensatory overeating at the next meal (Isakov et al., Clinical Nutrition ESPEN, 2026; PMID 42674358).
This is a single trial in a specific patient population, and the results should be interpreted as preliminary evidence rather than a definitive conclusion. The trial’s design — a controlled crossover with continuous glucose monitoring — provides stronger internal validity than an observational study, but replication in larger and more diverse populations is needed before broad clinical recommendations can be made.
Safety and Allergenicity
As a protein, brazzein carries a theoretical risk of allergenicity — any protein can be an allergen in susceptible individuals. The systematic review by Hidayati et al. (2026) assessed brazzein alongside other plant-derived sweet proteins and found that the allergenic potential is low based on in silico sequence homology, in vitro IgE-binding studies and clinical data. However, the review noted that clinical data on brazzein specifically are limited, and individual cases of sensitisation cannot be ruled out.
For patients with known food protein allergies — particularly to plant proteins — a cautious approach is warranted. As with any novel ingredient, the first exposure should be in a controlled setting with appropriate observation.
Brazzein vs Artificial Sweeteners: A Comparison
| Property | Brazzein | Aspartame | Sucralose | Saccharin |
|---|---|---|---|---|
| Source | Plant protein (natural) | Synthetic dipeptide | Chlorinated sucrose derivative | Synthetic sulfonamide |
| Sweetness (vs sucrose) | 500–2,000× | 200× | 600× | 300× |
| Calories | 0 (protein digested) | 4 kcal/g (negligible per serving) | 0 | 0 |
| Heat stability | Stable to 98°C | Degrades with heat | Stable | Stable |
| Glycaemic effect | None (trial-confirmed) | None | None | None |
| PKU concern | No (protein, not phenylalanine-based) | Contains phenylalanine — unsafe for PKU | No | No |
| Gut microbiome impact | Minimal (digested as protein) | Some evidence of alteration | Some evidence of alteration | Limited data |
| Aftertaste | Clean, sugar-like | Slight bitter/metallic | Slight bitter | Strong bitter/metallic |
Clinical Applications Where Brazzein May Be Relevant
Patients with Phenylketonuria (PKU)
Aspartame contains phenylalanine and is unsafe for patients with PKU. Brazzein, as a protein composed of multiple amino acids including phenylalanine, also contains phenylalanine — but at levels comparable to any dietary protein. The difference is that brazzein is consumed in microgram-to-milligram quantities per serving (due to its extreme sweetness), so the phenylalanine load is negligible. For PKU patients who need to avoid aspartame, brazzein offers a sweetening option that does not add a significant phenylalanine burden.
Patients with Migraine Triggers
Some artificial sweeteners — particularly aspartame — have been reported as migraine triggers in susceptible individuals. Brazzein, as a protein, does not share the same chemical structure and is less likely to trigger migraines through the same mechanism, though individual responses vary.
Patients Concerned About Gut Microbiome Effects
Emerging evidence suggests that some non-nutritive sweeteners — including sucralose and saccharin — can alter the composition and function of the gut microbiome. Brazzein, being a protein that is digested and absorbed in the small intestine, is unlikely to reach the colon in significant amounts and therefore is less likely to affect the gut microbiome.
Patients Seeking a “Clean Label” Sweetener
For patients who prefer ingredients that are naturally derived rather than synthetically manufactured, brazzein — as a plant-derived protein — aligns with a clean-label preference. It is not a synthetic chemical; it is a protein that the body processes through normal digestive pathways.
Discussing a Brazzein-Containing Formulation with Lynnity
For practitioners in Kuala Lumpur and the Klang Valley who have patients needing a protein-based sweetener alternative — whether for PKU management, migraine prevention, metabolic health or personal preference — Lynnity Compounding Pharmacy can incorporate brazzein into customised supplement formulations, including oral liquids, capsules and flavoured preparations. The preparation is made on a registered doctor’s prescription under Good Compounding Practice (GCP), for one named patient. Lynnity also prepares customised supplement formulations with precise active-ingredient specifications, excipient profiles and delivery forms.
To initiate a preparation, the prescriber submits a prescription specifying the desired formulation, brazzein concentration and any accompanying active ingredients. Lynnity’s compounding pharmacists then formulate, label and dispense the preparation with appropriate beyond-use dating and patient counselling.
Frequently Asked Questions
Is brazzein safe for patients with phenylketonuria (PKU)?
Brazzein contains phenylalanine as part of its protein structure, but the amount consumed per serving is negligible — in the microgram range — because brazzein is 500–2,000 times sweeter than sugar. This is far below the phenylalanine threshold that would concern PKU management. However, each patient’s individual tolerance should be assessed by their metabolic specialist.
Does brazzein raise blood glucose or insulin?
A randomised controlled trial in patients with MASLD found that brazzein-sweetened ice cream produced a significantly lower glycaemic response than sucrose-sweetened ice cream. As a protein, brazzein does not provide digestible carbohydrate and does not raise blood glucose.
Is brazzein suitable for cooking and baking?
Yes. Brazzein is heat-stable and retains its sweetness after heating to 98°C for 2 hours, making it suitable for use in cooked and baked products. This is an advantage over aspartame, which degrades with heat.
Can brazzein cause allergic reactions?
As a protein, brazzein carries a theoretical risk of allergenicity. A systematic review of plant-derived sweet proteins assessed brazzein’s allergenic potential as low, but clinical data specific to brazzein are limited. Patients with known food protein allergies should exercise caution with first exposure.
Does Lynnity compound brazzein formulations for patients in Singapore?
Lynnity accepts enquiries from Singapore-based practitioners. A valid Malaysian prescription from a registered doctor is required for any compounded preparation. Singapore-based clinicians should consult with a Malaysian-registered prescriber regarding the referral pathway.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific brazzein-containing formulation, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.